News
You may have heard of "Ozempic face" and "Ozempic butt." Well, now there's "Ozempic mouth" and "Ozempic feet" to describe ...
Nationally representative survey data revealed that glucagon-like peptide 1 receptor agonists (GLP-1 RAs) use for obesity ...
The rise in GLP-1 use among young women raises concerns about contraceptive efficacy and potential pregnancy risks. Learn ...
When it came to cardiovascular incidents, the report showed major gains for GLP-1 users, too. 44% experienced fewer ...
Full Frame Growth Partners is a minority investor in California-based Supergut, a company making powdered supplements and ...
18h
Civic Science on MSNGLP-1 Trends by CivicScience: Costs Emerge as a Barrier Amid Uncertainty, But Emotional Wellbeing ImprovesThis is just a tiny glimpse of the data available to CivicScience clients. Discover more data. CivicScience has data on more ...
More and more companies are investing in developing GLP-1R agonists, including dual and triple agonists and combination ...
India conducted strikes on nine terrorist sites in Pakistan. The action comes in response to the terrorist attack in Pahalgam ...
Bariatric surgery and GLP-1s conferred similar outcomes in mortality, adverse cardiovascular events and cirrhosis development ...
Weightloss drugs can also cause what is known as Ozempic hands. As with the feet and face, these areas show fat loss more ...
Novo Nordisk (NYSE:NVO) trimmed its full-year 2025 sales and profit forecast on Wednesday, citing weaker-than-expected U.S.
The use of GLP-1s among patients with type 2 diabetes appeared associated with significantly reduced risk for certain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results